Supporting the implication of IL-17 in the metabolic syndrome, the levels of IL-17R expression in liver or muscle were shown to correlate with insulin-resistance [52], and IL-17 blocking resulted in the decrease of hepatic inflammation in the non-alcoholic steatohepatitis syndrome (NASH) [54]. This evidence concerns the gene IL17A and metabolic syndrome.